Interferon lambda: A new sword in cancer immunotherapy

Clinical and Developmental Immunology

Volumn 2011, Issue , 2011, Pages

  Lasfar, Ahmed ^a   Abushahba, Walid ^b   Balan, Murugabaskar ^b   Cohen Solal, Karine A ^b  

^a University of Medicine and Dentistry of New Jersey   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA RECEPTOR; INTERFERON RECEPTOR; RIBAVIRIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL SPECIFICITY; CELL TYPE; CELLULAR IMMUNITY; CHRONIC GRANULOMATOUS DISEASE; CONDYLOMA ACUMINATUM; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; EPITHELIUM CELL; HEPATITIS B; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG METASTASIS; MELANOMA; MULTIPLE SCLEROSIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; DRUG POTENTIATION; IMMUNOTHERAPY; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERFERONS; NEOPLASMS;

EID: 84855568706     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/349575     Document Type: Review

References (96)

1. Donnelly R. P., Kotenko S. V., Interferon-lambda: a new addition to an old family Journal of Interferon and Cytokine Research 2010 30 8 555 564
2. Kotenko S. V., Gallagher G., Baurin V. V., Lewis-Antes A., Shen M., Shah N. K., Langer J. A., Sheikh F., Dickensheets H., Donnelly R. P., IFN- s mediate antiviral protection through a distinct class II cytokine receptor complex Nature Immunology 2003 4 1 69 77 (Pubitemid 36109115)
3. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T. E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F. J., Tackett M., Krivan W., McKnight G., Clegg C., Foster D., Klucher K. M., IL-28, IL-29 and their class II cytokine receptor IL-28R Nature Immunology 2003 4 1 63 68 (Pubitemid 36104710)
4. Lasfar A., Lewis-Antes A., Smirnov S. V., Anantha S., Abushahba W., Tian B., Reuhl K., Dickensheets H., Sheikh F., Donnelly R. P., Raveche E., Kotenko S. V., Characterization of the mouse IFN- ligand-receptor system: IFN- s exhibit antitumor activity against B16 melanoma Cancer Research 2006 66 8 4468 4477
5. Ank N., Iversen M. B., Bartholdy C., Staeheli P., Hartmann R., Jensen U. B., Dagnaes-Hansen F., Thomsen A. R., Chen Z., Haugen H., Klucher K., Paludan S. R., An important role for type III interferon (IFN- /IL-28) in TLR-induced antiviral activity Journal of Immunology 2008 180 4 2474 2485
6. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A. R., Paludan S. R., Lambda interferon (IFN- ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo Journal of Virology 2006 80 9 4501 4509
7. Kugel D., Kochs G., Obojes K., Roth J., Kobinger G. P., Kobasa D., Haller O., Staeheli P., Von Messling V., Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets Journal of Virology 2009 83 8 3843 3851
8. Mordstein M., Kochs G., Dumoutier L., Renauld J. C., Paludan S. R., Klucher K., Staeheli P., Interferon- contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses PLoS Pathogens 2008 4 9
9. Li M., Liu X., Zhou Y., Shao B. S., Interferon- s: the modulators of antivirus, antitumor, and immune responses Journal of Leukocyte Biology 2009 86 1 23 32
10. Uzé G., Monneron D., IL-28 and IL-29: newcomers to the interferon family Biochimie 2007 89 6-7 729 734 (Pubitemid 47001631)
11. Hong S. H., Cho O., Kim K., Shin H. J., Kotenko S. V., Park S., Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells Virus Research 2007 126 1-2 245 249 (Pubitemid 46726717)
12. Lzaro C. A., Chang M., Tang W., Campbell J., Sullivan D. G., Gretch D. R., Corey L., Coombs R. W., Fausto N., Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes American Journal of Pathology 2007 170 2 478 489 (Pubitemid 47339385)
13. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E. S., Kotenko S. V., Macdonald M. R., Rice C. M., Interferons and inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 2006 131 6 1887 1898 (Pubitemid 44958521)
14. Robek M. D., Boyd B. S., Chisari F. V., Lambda interferon inhibits hepatitis B and C virus replication Journal of Virology 2005 79 6 3851 3854 (Pubitemid 40327973)
15. Hou W., Wang X., Ye L., Zhou L., Yang Z. Q., Riedel E., Ho W. Z., Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages Journal of Virology 2009 83 8 3837 3842
16. Li J., Hu S., Zhou L., Ye L., Wang X., Ho J., Ho W., Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons Glia 2011 59 1 58 67
17. Meager A., Visvalingam K., Dilger P., Bryan D., Wadhwa M., Biological activity of interleukins-28 and -29: comparison with type I interferons Cytokine 2005 31 2 109 118 (Pubitemid 40910226)
18. Maher S. G., Sheikh F., Scarzello A. J., Romero-Weaver A. L., Baker D. P., Donnelly R. P., Gamero A. M., IFN and IFN differ in their antiproliferative effects and duration of JAK/STAT signaling activity Cancer Biology and Therapy 2008 7 7 1109 1115
19. Biron C. A., Interferons and as immune regulatorsa new look Immunity 2001 14 6 661 664 (Pubitemid 32592413)
20. Le Bon A., Tough D. F., Links between innate and adaptive immunity via type I interferon Current Opinion in Immunology 2002 14 4 432 436 (Pubitemid 34671244)
21. Jordan W. J., Eskdale J., Boniotto M., Rodia M., Kellner D., Gallagher G., Modulation of the human cytokine response by interferon lambda-1 (IFN- 1/IL-29) Genes and Immunity 2007 8 1 13 20 (Pubitemid 46164287)
22. Megjugorac N. J., Gallagher G. E., Gallagher G., Modulation of human plasmacytoid DC function by IFN- 1 (IL-29) Journal of Leukocyte Biology 2009 86 6 1359 1363
23. Dai J., Megjugorac N. J., Gallagher G. E., Yu R. Y. L., Gallagher G., IFN- 1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells Blood 2009 113 23 5829 5838
24. Jordan W. J., Eskdale J., Srinivas S., Pekarek V., Kelner D., Rodia M., Gallagher G., Human interferon lambda-1 (IFN- 1/IL-29) modulates the Th1/Th2 response Genes and Immunity 2007 8 3 254 261 (Pubitemid 46679436)
25. Srinivas S., Dai J., Eskdale J., Gallagher G. E., Megjugorac N. J., Gallagher G., Interferon- 1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro Immunology 2008 125 4 492 502
26. Bullens D. M. A., Decraene A., Dilissen E., Meyts I., De Boeck K., Dupont L. J., Ceuppens J. L., Type III IFN- mRNA expression in sputum of adult and school-aged asthmatics Clinical and Experimental Allergy 2008 38 9 1459 1467
27. Johnston S. L., Innate immunity in the pathogenesis of virus-induced asthma exacerbations Proceedings of the American Thoracic Society 2007 4 3 267 270 (Pubitemid 47036447)
28. Coccia E. M., Severa M., Giacomini E., Monneron D., Remoli M. E., Julkunen I., Cella M., Lande R., Uzé G., Viral infection and toll-like receptor agonists induce a differential expression of type I and interferons in humans plasmacytoid and monocyte-derived dendritic cells European Journal of Immunology 2004 34 3 796 805 (Pubitemid 39255927)
29. Mennechet F. J. D., Uzé G., Interferon- -treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells Blood 2006 107 11 4417 4423 (Pubitemid 43801368)
30. Morrow M. P., Pankhong P., Laddy D. J., Schoenly K. A., Yan J., Cisper N., Weiner D. B., Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity Blood 2009 113 23 5868 5877
31. Der S. D., Zhou A., Williams B. R. G., Silverman R. H., Identification of genes differentially regulated by interferon,, or using oligonucleotide arrays Proceedings of the National Academy of Sciences of the United States of America 1998 95 26 15623 15628 (Pubitemid 29018750)
32. Doyle S. E., Schreckhise H., Khuu-Duong K., Henderson K., Rosler R., Storey H., Yao L., Liu H., Barahmand-Pour F., Sivakumar P., Chan C., Birks C., Foster D., Clegg C. H., Wietzke-Braun P., Mihm S., Klucher K. M., Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes Hepatology 2006 44 4 896 906 (Pubitemid 46489554)
33. Clemens M. J., Interferons and apoptosis Journal of Interferon and Cytokine Research 2003 23 6 277 292 (Pubitemid 36760748)
34. Kalvakolanu D. V., The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression Cytokine and Growth Factor Reviews 2004 15 2-3 169 194 (Pubitemid 38521252)
35. Dumoutier L., Tounsi A., Michiels T., Sommereyns C., Kotenko S. V., Renauld J. C., Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon- 1. Similarities with type 1 interferon signaling Journal of Biological Chemistry 2004 279 31 32269 32274 (Pubitemid 39014676)
36. Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S. T., Otte J. M., Diebold J., Diepolder H., Adler B., Auernhammer C. J., Gke B., Dambacher J., IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression American Journal of Physiology 2005 289 5 G960 G968
37. Zitzmann K., Brand S., Baehs S., Gke B., Meinecke J., Spttl G., Meyer H., Auernhammer C. J., Novel interferon- s induce antiproliferative effects in neuroendocrine tumor cells Biochemical and Biophysical Research Communications 2006 344 4 1334 1341
38. Li W., Lewis-Antes A., Huang J., Balan M., Kotenko S. V., Regulation of apoptosis by type III interferons Cell Proliferation 2008 41 6 960 979
39. Novak A. J., Grote D. M., Ziesmer S. C., Rajkumar V., Doyle S. E., Ansell S. M., A role for IFN- 1 in multiple myeloma B cell growth Leukemia 2008 22 12 2240 2246
40. Sommereyns C., Paul S., Staeheli P., Michiels T., IFN-lambda (IFN- ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo PLoS Pathogens 2008 4 3
41. Pott J., Mahlakiv T., Mordstein M., Duerr C. U., Michiels T., Stockinger S., Staeheli P., Hornef M. W., IFN- determines the intestinal epithelial antiviral host defense Proceedings of the National Academy of Sciences of the United States of America 2011 108 19 7944 7949
42. Jewell N. A., Cline T., Mertz S. E., Smirnov S. V., Flao E., Schindler C., Grieves J. L., Durbin R. K., Kotenko S. V., Durbin J. E., Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo Journal of Virology 2010 84 21 11515 11522
43. Pulverer J. E., Rand U., Lienenklaus S., Kugel D., Zitara N., Kochs G., Naumann R., Weiss S., Staeheli P., Hauser H., Kster M., Temporal and spatial resolution of type I and III interferon responses in vivo Journal of Virology 2010 84 17 8626 8638
44. Koltsida O., Hausding M., Stavropoulos A., Koch S., Tzelepis G., bel C., Kotenko S. V., Sideras P., Lehr H. A., Tepe M., Klucher K. M., Doyle S. E., Neurath M. F., Finotto S., Andreakos E., IL-28A (IFN- 2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease EMBO Molecular Medicine 2011 3 6 348 361
45. Abushahba W., Balan M., Castaneda I., Yuan Y., Reuhl K., Raveche E., De La Torre A., Lasfar A., Kotenko S. V., Antitumor activity of type I and type III interferons in BNL hepatoma model Cancer Immunology, Immunotherapy 2010 59 7 1059 1071
46. Witte K., Gruetz G., Volk H. D., Looman A. C., Asadullah K., Sterry W., Sabat R., Wolk K., Despite IFN-receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines Genes and Immunity 2009 10 8 702 714
47. Wolk K., Witte K., Witte E., Proesch S., Schulze-Tanzil G., Nasilowska K., Thilo J., Asadullah K., Sterry W., Volk H. D., Sabat R., Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes Journal of Leukocyte Biology 2008 83 5 1181 1193 (Pubitemid 351960350)
48. Dellgren C., Gad H. H., Hamming O. J., Melchjorsen J., Hartmann R., Human interferon- 3 is a potent member of the type III interferon family Genes and Immunity 2009 10 2 125 131
49. Thomas C., Moraga I., Levin D., Krutzik P. O., Podoplelova Y., Trejo A., Lee C., Yarden G., Vleck S. E., Glenn J. S., Nolan G. P., Piehler J., Schreiber G., Garcia K. C., Structural linkage between ligand discrimination and receptor activation by type I interferons Cell 2011 146 4 621 632
50. Mordstein M., Neugebauer E., Ditt V., Jessen B., Rieger T., Falcone V., Sorgeloos F., Ehl S., Mayer D., Kochs G., Schwemmle M., Gnther S., Drosten C., Michiels T., Staeheli P., Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections Journal of Virology 2010 84 11 5670 5677
51. Muir A. J., Shiffman M. L., Zaman A., Yoffe B., De La Torre A., Flamm S., Gordon S. C., Marotta P., Vierling J. M., Lopez-Talavera J. C., Byrnes-Blake K., Fontana D., Freeman J., Gray T., Hausman D., Hunder N. N., Lawitz E., Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection Hepatology 2010 52 3 822 832
52. Kelly C., Klenerman P., Barnes E., Interferon lambdas: the next cytokine storm Gut 2011 60 9 1284 1293
53. Ge D., Fellay J., Thompson A. J., Simon J. S., Shianna K. V., Urban T. J., Heinzen E. L., Qiu P., Bertelsen A. H., Muir A. J., Sulkowski M., McHutchison J. G., Goldstein D. B., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 2009 461 7262 399 401
54. Labie D., Gilgenkrantz H., IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C Médecine Sciences 2010 26 3 225 226
55. Mangia A., Thompson A. J., Santoro R., Piazzolla V., Tillmann H. L., Patel K., Shianna K. V., Mottola L., Petruzzellis D., Bacca D., Carretta V., Minerva N., Goldstein D. B., McHutchison J. G., An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response Gastroenterology 2010 139 3 821 e1
56. McCarthy J. J., Li J. H., Thompson A., Suchindran S., Lao X. Q., Patel K., Tillmann H. L., Muir A. J., McHutchison J. G., Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin Gastroenterology 2010 138 7 2307 2314
57. Montes-Cano M. A., Garca-Lozano J. R., Abad-Molina C., Romero-Gmez M., Barroso N., Aguilar-Reina J., Nez-Roldn A., Gonzlez-Escribano M. F., Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes Hepatology 2010 52 1 33 37
58. Mosbruger T. L., Duggal P., Goedert J. J., Kirk G. D., Hoots W. K., Tobler L. H., Busch M., Peters M. G., Rosen H. R., Thomas D. L., Thio C. L., Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus Journal of Infectious Diseases 2010 201 9 1371 1380
59. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J., Furrer H., Gnthard H. F., Heim M., Hirschel B., Malinverni R., Moradpour D., Mllhaupt B., Witteck A., Beckmann J. S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P., Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 2010 138 4 1338 1345
60. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M. L., Bassendine M., Spengler U., Dore G. J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Mller T., Bahlo M., Stewart G. J., Booth D. R., George J., IL28B is associated with response to chronic hepatitis C interferon- and ribavirin therapy Nature Genetics 2009 41 10 1100 1104
61. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M., Genome-wide association of IL28B with response to pegylated interferon- and ribavirin therapy for chronic hepatitis C Nature Genetics 2009 41 10 1105 1109
62. Lasfar A., Abushahba W., de la Torre A., Castaneda I., Kotenko S. V., Reuhl K., IFN therapy in TIB75 HCC model: combination of IFN-lambda and IFN-alpha induces complete remission Hepathology 2008 48 4, supplement, #191
63. Kirkwood J. M., Ibrahim J., Lawson D. H., Atkins M. B., Agarwala S. S., Collins K., Mascari R., Morrissey D. M., Chapman P. B., High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter eastern cooperative oncology group phase II trial E2696 Journal of Clinical Oncology 2001 19 5 1430 1436 (Pubitemid 32202550)
64. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H., Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684 Journal of Clinical Oncology 1996 14 1 7 17 (Pubitemid 26019991)
65. Moschos S., Varanasi S., Kirkwood J. M., Interferons in the treatment of solid tumors Cancer Treatment and Research 2005 126 207 241
66. Cascinelli N., Belli F., MacKie R. M., Santinami M., Bufalino R., Morabito A., Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial Lancet 2001 358 9285 866 869 (Pubitemid 32900567)
67. Kleeberg U. R., Suciu S., Brcker E. B., Ruiter D. J., Chartier C., Liénard D., Marsden J., Schadendorf D., Eggermont A. M.M., Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN- 2b versus rIFN- versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness 3 mm) or regional lymph node metastasis European Journal of Cancer 2004 40 3 390 402 (Pubitemid 38121277)
68. Sato A., Ohtsuki M., Hata M., Kobayashi E., Murakami T., Antitumor activity of IFN- in murine tumor models Journal of Immunology 2006 176 12 7686 7694 (Pubitemid 43849069)
69. Numasaki M., Tagawa M., Iwata F., Suzuki T., Nakamura A., Okada M., Iwakura Y., Aiba S., Yamaya M., IL-28 elicits antitumor responses against murine fibrosarcoma Journal of Immunology 2007 178 8 5086 5098 (Pubitemid 46595292)
70. Farazi P. A., DePinho R. A., Hepatocellular carcinoma pathogenesis: from genes to environment Nature Reviews Cancer 2006 6 9 674 687 (Pubitemid 44286000)
71. Lau W. Y., Lai E. C. H., Hepatocellular carcinoma: current management and recent advances Hepatobiliary and Pancreatic Diseases International 2008 7 3 237 257 (Pubitemid 351895383)
72. Sherman M., Hepatocellular carcinoma: epidemiology, risk factors, and screening Seminars in Liver Disease 2005 25 2 143 154 (Pubitemid 40781067)
73. Mazzaferro V., Chun Y. S., Poon R. T. P., Schwartz M. E., Yao F. Y., Marsh J. W., Bhoori S., Lee S. G., Liver transplantation for hepatocellular carcinoma Annals of Surgical Oncology 2008 15 4 1001 1007
74. Mazzaferro V., Llovet J. M., Miceli R., Bhoori S., Schiavo M., Mariani L., Camerini T., Roayaie S., Schwartz M. E., Grazi G. L., Adam R., Neuhaus P., Salizzoni M., Bruix J., Forner A., De Carlis L., Cillo U., Burroughs A. K., Troisi R., Rossi M., Gerunda G. E., Lerut J., Belghiti J., Boin I., Gugenheim J., Rochling F., Van Hoek B., Majno P., Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis The Lancet Oncology 2009 10 1 35 43
75. Taketomi A., Soejima Y., Yoshizumi T., Uchiyama H., Yamashita Y. I., Maehara Y., Liver transplantation for hepatocellular carcinoma Journal of Hepato-Biliary-Pancreatic Surgery 2008 15 2 124 130 (Pubitemid 351516969)
76. Georgiades C. S., Hong K., Geschwind J. F., Radiofrequency ablation and chemoembolization for hepatocellular carcinoma Cancer Journal 2008 14 2 117 122
77. Di Bisceglie A. M., Carithers R. L., Gores G. J., Hepatocellular carcinoma Hepatology 1998 28 4 I 1161 1165 (Pubitemid 28450282)
78. Nagai H., Sumino Y., Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy Recent Patents on Anti-Cancer Drug Discovery 2008 3 3 220 226
79. El-Serag H. B., Hepatocellular carcinoma: an epidemiologic view Journal of Clinical Gastroenterology 2002 35 5 S72 S78
80. Wang L., Wu W. Z., Sun H. C., Wu X. F., Qin L. X., Liu Y. K., Liu K. D., Tang Z. Y., Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice Journal of Gastrointestinal Surgery 2003 7 5 587 594 (Pubitemid 36875750)
81. Fattovich G., Giustina G., Sanchez-Tapias J., Quero C., Mas A., Olivotto P. G., Solinas A., Almasio P., Hadziyannis S., Degos F., De Moura M. C., Krogsgaard K., Pantalena M., Realdi G., Corrocher R., Schalm S. W., Crax A., Delarocque E., Savvas S., Cossu P., Tocco A., Olsen J., Christensen E., Rocha P., Delayed clearance of serum HBsAG in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis The American Journal of Gastroenterology 1998 93 6 896 900 (Pubitemid 29076972)
82. Lin S. M., Yu M. L., Lee C. M., Chien R. N., Sheen I. S., Chu C. M., Liaw Y. F., Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma Journal of Hepatology 2007 46 1 45 52
83. Omata M., Yoshida H., Shiratori Y., Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy Clinical Gastroenterology and Hepatology 2005 3 2 S141 S143
84. Yu M. L., Lin S. M., Chuang W. L., Dar C. Y., Wang J. H., Lu S. N., Sheen I. S., Chang W. Y., Lee C. M., Liaw Y. F., A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan Antiviral Therapy 2006 11 8 985 994
85. Llovet J. M., Sala M., Castells L., Suarez Y., Vilana R., Bianchi L., Ayuso C., Vargas V., Rodés J., Bruix J., Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma Hepatology 2000 31 1 54 58 (Pubitemid 30033689)
86. Lo C. M., Liu C. L., Chan S. C., Lam C. M., Poon R. T. P., Ng I. O. L., Fan S. T., Wong J., A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma Annals of Surgery 2007 245 6 831 842 (Pubitemid 46809282)
87. Ueshima K., Kudo M., Nagai T., Tatsumi C., Ueda T., Takahashi S., Hatanaka K., Kitai S., Ishikawa E., Inoue T., Hagiwara S., Minami Y., Chung H., Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma Oncology 2008 75 1 106 113
88. Sidky Y. A., Borden E. C., Inhibition of angiogenesis by interfersons: effects on tumor- and lymphocyte-induced vascular responses Cancer Research 1987 47 19 5155 5161 (Pubitemid 17146488)
89. Dinney C. P. N., Bielenberg D. R., Perrotte P., Reich R., Eve B. Y., Bucana C. D., Fidler I. J., Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon- administration Cancer Research 1998 58 4 808 814 (Pubitemid 28099496)
90. Dong Y., Rohn W. M., Benveniste E. N., IFN- regulation of the type IV class II transactivator promoter in astrocytes Journal of Immunology 1999 162 8 4731 4739 (Pubitemid 29314874)
91. Gresser I., Antitumour effects of interferons: past, present and future British Journal of Haematology, Supplement 1991 79 1 1 5
92. Gresser I., Kaido T., Maury C., Woodrow D., Moss J., Belardelli F., Interaction of IFN / with host cells essential to the early inhibition of friend erythroleukemia visceral metastases in mice International Journal of Cancer 1994 57 4 604 611 (Pubitemid 24173110)
93. Kaido T., Maury C., Schirrmacher V., Gresser I., Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8 + T cells and IFN- / International Journal of Cancer 1994 57 4 538 543 (Pubitemid 24173100)
94. Kaido T. J., Maury C., Gresser I., Host CD4 + T lymphocytes are required for the synergistic action of interferon / and adoptively transferred immune cells in the inhibition of visceral ESb metastases Cancer Research 1995 55 24 6133 6139
95. Javelaud D., Alexaki V. I., Mauviel A., Transforming growth factor- in cutaneous melanoma Pigment Cell Melanoma Research 2008 21 2 123 132 (Pubitemid 351551229)
96. Lasfar A., Cohen-Solal K. A., Resistance to transforming growth factor -mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis 2010 31 10 1710 1717